Part of InSilicoNEURO, MS TreatSim can optimize clinical trials on MS patients, while helping pharmaceutical companies and CROs significantly reduce their cost and timeframe
InSilicoTrials keeps releasing new, highly reliable and efficient digital tools for the healthcare sector that leverage modeling & simulation. The latest product – called Multiple Sclerosis Treatment Simulator or MS TreatSim – is going to optmize clinical trials on patients suffering from Multiple Sclerosis.
In silico methods, greatly recommended by all regulatory agencies, can help pharmaceutical companies and CROs reduce the time and cost of drug development up to 50%, thanks to the unique Insilicotrials.com platform, which is incredibly easy to use and cost-effective.
Multiple Sclerosis currently affects 2.8 million people worldwide, especially adults of ages 20-50, and 2-3 times as many women as men. Every 5 minutes someone is diagnosed with MS, and there are huge differences between the patients. Some of them live out their lives relatively normally, while others experience a rapid onset of disability and eventually die. Most MS patients experience relapses – temporary sudden onsets of symptoms – followed by remission periods, in which most or all of these symptoms disappear.
For a long time, it was difficult to treat MS, but patient’s outlooks have improved a great deal. In the last decade about 10 new drugs for MS were approved. MS drugs have had a much higher success rate in passing through clinical trials (about 27%) than average (10%). But developing a drug for MS is not easy at all and clinical trials still present huge challenges.
This is why MS TreatSim, part of InSilicoNEURO – a series of simulation products dedicated to neurodegenerative diseases – could be a real game-changer. MS TreatSim is the result of a collaboration between University of Catania’s spin-off Mimesis and InSilicoTrials Technologies.
MS TreatSim enables simulation of realistic disease courses in Relapsing-Remitting Multiple Sclerosis (RRMS), based on a mechanistic model of the immune system and its dysregulation in MS.
The model incorporates the adaptive and innate immune system, the autoimmune response and four distinct disease modifying therapies. The relapse rates predicted by the model have been validated with individual clinical data, as well as clinical trial data.
MS TreatSim combines two different types of simulation workflows: In Silico Trial enables simu- lation of clinical trials with heterogeneous populations of virtual RRMS patients; Digital Twin is designed for exploring the effect of treatment strategies at the individual level.
“After the launch of InSilicoCARDIO in 2020 and InSilicoONCO last October, we are proud to present InSilicoNEURO, our series of simulation tools dedicated to neurological disorders”, says Luca Emili, CEO and Founder of InSilicoTrials. “We constantly work with regulatory agencies such as FDA and EMA and with an international network of prestigious universities, which provide us with the best computational models. Our huge expertise in life sciences R&D and in IT/SaaS development is another key factor that makes our company a game-changer in the healthcare industry”.
